Clinical Social Workers in Duncanville, TX Accepting Medicare

6 Clinical Social Workers found. Showing 1 - 6

Joyce Elaine West, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1222 Bow Creek Dr, Duncanville, TX 75116 Phone: 972-709-6147

Mrs. Sylvia Calderon Foladare, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 407 N Cedar Ridge Dr, Suite 200, Duncanville, TX 75116 Phone: 972-709-4446    Fax: 972-296-1832

Zephyr Leacarol Carson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 218 Roma Dr, Duncanville, TX 75116 Phone: 817-308-1090

Ms. Sheri Lynn Sloan, L.C.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 402 W Wheatland Rd Ste 160, Duncanville, TX 75116 Phone: 972-298-9989    Fax: 972-298-0773

Mrs. Yalanda Griffin Henderson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 407 N Cedar Ridge Dr, Ste 227, Duncanville, TX 75116 Phone: 972-502-4020    Fax: 214-330-4671

Mr. Gary W. Stephens, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 402 W Wheatland Rd, Duncanville, TX 75116 Phone: 214-813-7854    Fax: 972-283-1891

News Archive

Study finds reductions in volume of gray matter in the brains of children with obstructive sleep apnea

A study comparing children between 7 and 11 years of age who have moderate or severe obstructive sleep apnea to children the same age who slept normally, found significant reductions of gray matter - brain cells involved in movement, memory, emotions, speech, perception, decision making and self-control - in several regions of the brains of children with sleep apnea.

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies.

Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide.

Kaiser summarizes editorials on CDC routine HIV testing recommendations

Two newspapers recently published editorials regarding the new CDC HIV testing recommendations.

'Energy poverty' leaves more than 1B in developing countries without access to adequate health care, report says

"Energy poverty has left more than one billion people in developing countries without access to adequate health care, with staff forced to treat emergency patients in the dark, and health centers lacking the power they need to store vaccines or sterilize medical supplies, according to ... this year's Poor People's Energy Outlook, published on Wednesday by the non-governmental organization Practical Action," the Guardian reports.

Read more Medical News

› Verified 6 days ago